Biodesix receives CE Mark for diagnostic kit
Last Updated: 17:08 March 5, 2014
VeriStrat is a noninvasive diagnostic test that predicts whether patients with non-operable, advanced non-small cell lung cancer would be better served by chemotherapy or the drug erlotinib.
The VeriStrat results are used along with other factors to guide treatment decisions.
VeriStrat, according to a Biodesix press release, will help doctors consider ruling out the roughly 30 percent of NSCLC patients who are unlikely to benefit from erlotinib and should receive chemotherapy.
"Making VeriStrat results available to physicians for patients in the European Union has been an important goal for Biodesix," said David Brunel, chief executive of Biodesix. "With the CE Mark for the specimen collection and shipping kit, more physicians can incorporate this valuable new component into the set of tools they need to guide therapy. VeriStrat will allow them to make targeted, timely treatment decisions that can improve survival outcomes and potentially provide a higher quality of life."
More breaking news...
CEOs: Health care administrative costs still rising
Lacy replaces Kam Mofid, who left the company to pursue other interests, according to a
Brewery takes space in former Butterball building
New Belgium hosting roundtable on EPA water rule